Becton Dickinsonvs.Boston Scientific
BDX vs BSX · both in Medtech & devices, part of the Medicine, pharma & life science value chain: Medical equipment and devices, from surgery and cardiology to robotics.
Boston Scientific is about 1.5× larger than Becton Dickinson by market cap; Boston Scientific trades at the lower P/E (20.4 vs 53.2); year to date, Becton Dickinson leads (+25.0% vs −48.6%).
Side by side
| BDX | BSX | |
|---|---|---|
| Market cap | $50.1B | $75B |
| Price | $189.78 | $49.86 |
| Today | −0.5% | +1.7% |
| Return YTD | +25.0% | −48.6% |
| Return 1Y | +21.5% | −53.8% |
| P/E | 53.2 | 20.4 |
| P/S | 2.4 | 3.6 |
| P/B | 2.1 | 3.0 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Becton DickinsonBDX
Syringes and needles sit at the recognisable end of the range. Becton Dickinson's portfolio is broad, spanning medical consumables alongside diagnostic systems and drug delivery equipment.
Full BDX profile →Boston ScientificBSX
Cardiology drives the growth, particularly electrophysiology, where Farapulse sits, and structural heart treatment. Endoscopy and urology cover the rest of the range.
Full BSX profile →More BDX & BSX comparisons
Other head-to-heads in the Medtech & devices segment.